ONC201治疗H3 K27M突变弥漫性中线胶质瘤的初步临床验证
本研究通过扩大可及性方案,评估选择性DRD2/3拮抗剂ONC201在H3 K27M突变弥漫性中线胶质瘤患者中的疗效与安全性。结果提供了靶向该突变的初步临床概念验证。
要点
- ONC201在H3 K27M突变弥漫性中线胶质瘤中显示出初步影像学缓解和生存获益。
- 复发患者中位PFS 14周、OS 17周,部分成人持续无进展随访达49.6周。
- 放疗后辅助ONC201的儿童DIPG患者中两例无进展至少53和81周。
核心结论
- ONC201靶向H3 K27M突变弥漫性中线胶质瘤具有初步临床概念验证,无论年龄或肿瘤位置。
研究设计与样本
- 扩大可及性方案,纳入至少接受过放疗的H3 K27M突变胶质瘤患者,排除软脑膜播散者。
- 截至2018年8月共纳入18例患者:7例成人(>20岁)和7例儿童(<20岁)为复发后开始ONC201,4例儿童为放疗后未复发时开始。
- 所有患者每周口服ONC201,至少每8周评估安全性、影像学和总生存期。
主要发现
- 14例复发患者中位无进展生存期14周,中位总生存期17周。
- 14例复发患者中3例成人持续无进展,中位随访49.6周(范围41-76.1周)。
- 4例放疗后辅助ONC201的儿童中,2例DIPG患者无进展至少53周和81周。
- 研究者报告丘脑和脑桥胶质瘤患者出现影像学退缩,包括一例完全缓解,并伴有疾病相关神经症状改善。
临床怎么用
- 对于H3 K27M突变弥漫性中线胶质瘤,ONC201可作为基于初步证据的试验性治疗选择。
- 治疗期间需定期进行影像学评估和安全性监测。
局限性
- 样本量小(18例),为开放标签扩大可及性方案,非随机对照试验。
- 随访时间有限,部分患者仍在校验中。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: H3 K27M-mutant diffuse midline glioma is a fatal malignancy with no proven medical therapies. The entity predominantly occurs in children and young adults. ONC201 is a small molecule selective antagonist of dopamine receptor D2/3 (DRD2/3) with an exceptional safety profile. Following up on a durable response in the first H3 K27M-mutant diffuse midline glioma patient who received ONC201 (NCT02525692), an expanded access program was initiated. METHODS: Patients with H3 K27M-mutant gliomas who received at least prior radiation were eligible. Patients with leptomeningeal spread were excluded. All patients received open-label ONC201 orally once every week. Safety, radiographic assessments, and overall survival were regularly assessed at least every 8 weeks by investigators. As of August 2018, a total of 18 patients with H3 K27M-mutant diffuse midline glioma or DIPG were enrolled to single patient expanded access ONC201 protocols. Among the 18 patients: seven adult (> 20 years old) and seven pediatric (< 20 years old) patients initiated ONC201 with recurrent disease and four pediatric patients initiated ONC201 following radiation, but prior to disease recurrence. FINDINGS: Among the 14 patients with recurrent disease prior to initiation of ONC201, median progression-free survival is 14 weeks and median overall survival is 17 weeks. Three adults among the 14 recurrent patients remain on treatment progression-free with a median follow up of 49.6 (range 41-76.1) weeks. Among the 4 pediatric patients who initiated adjuvant ONC201 following radiation, two DIPG patients remain progression-free for at least 53 and 81 weeks. Radiographic regressions, including a complete response, were reported by investigators in a subset of patients with thalamic and pontine gliomas, along with improvements in disease-associated neurological symptoms. INTERPRETATION: The clinical outcomes and radiographic responses in these patients provide the preliminary, and initial clinical proof-of-concept for targeting H3 K27M-mutant diffuse midline glioma with ONC201, regardless of age or location, providing rationale for robust clinical testing of the agent.
引用
- Chi AS, Tarapore RS, Hall MD, et al. Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201. J Neurooncol. 2019. PMID: 31456142. doi:10.1007/s11060-019-03271-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。